Fulgent Genetics (NASDAQ:FLGT) Releases FY25 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) issued an update on its FY25 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of $(0.65) for the period, compared to the consensus estimate of ($0.15). The company issued revenue guidance of $310.0 million, compared to the consensus revenue estimate of $324.65 million. Fulgent Genetics also updated its FY 2025 guidance to -0.650–0.650 EPS.

Fulgent Genetics Stock Down 2.4 %

NASDAQ:FLGT traded down $0.38 during mid-day trading on Friday, reaching $15.32. 299,261 shares of the company were exchanged, compared to its average volume of 195,220. Fulgent Genetics has a 12 month low of $15.32 and a 12 month high of $25.11. The company has a fifty day moving average of $17.37 and a 200 day moving average of $19.55. The stock has a market cap of $468.44 million, a PE ratio of -2.78 and a beta of 1.39.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on FLGT shares. StockNews.com lowered shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th. Piper Sandler reduced their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.